Dynamic tailoring of treatment durations improves efficiency of hepatitis C treatment with pegylated interferon and ribavirin

Journal of Viral Hepatitis

Volumn 20, Issue 4, 2013, Pages

  Lindh, M ^a   Arnholm, B ^b   Bjorkman P ^c   Hellstrand, K ^a   Lagging, M ^a   Nilsson, S ^d   Wahlberg, T ^e   Wallmark, E ^c   Weiland, O ^f   Wejstal R ^a   Westin, J ^a   Widell, A ^c   Norkrans, G ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b BORÅS HOSPITAL   (Sweden)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

^d CHALMERS UNIVERSITY OF TECHNOLOGY   (Sweden)

^e CENTRAL HOSPITAL   (Sweden)

^f KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

HCV; interferon; kinetics; ribavirin; therapy

Indexed keywords

INTERLEUKIN 28B; PEGINTERFERON ALPHA2A; RIBAVIRIN; VIRUS RNA;

ADULT; ANEMIA; ANTIVIRAL THERAPY; ARTICLE; BODY MASS; CONTROLLED STUDY; DEPRESSION; FATIGUE; GENETIC POLYMORPHISM; GENOTYPE; HEALTH CARE QUALITY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IRRITABILITY; LIVER BIOPSY; MAJOR CLINICAL STUDY; MOOD CHANGE; MULTICENTER STUDY; PERSONALIZED MEDICINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; RELAPSE; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; VIRUS LOAD;

ADULT; AGED; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RIBAVIRIN; RNA, VIRAL; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD; YOUNG ADULT;

EID: 84875221731     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12014     Document Type: Article

References (17)

1. Ghany MG, Strader DB, Thomas DL, Seeff LB,. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335-1374.
2. Jensen DM, Morgan TR, Marcellin P, et al,. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology 2006; 43: 954-960.
3. Zeuzem S, Buti M, Ferenci P, et al,. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol 2006; 44: 97-103.
4. Berg T, von Wagner M, Nasser S, et al,. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology 2006; 130: 1086-1097.
5. Pearlman BL, Ehleben C, Saifee S,. Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis c genotype 1-infected slow responders. Hepatology 2007; 46: 1688-1694.
6. Sanchez-Tapias JM, Diago M, Escartin P, et al,. Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastroenterology 2006; 131: 451-460.
7. Ogawa E, Furusyo N, Toyoda K, et al,. Excellent superiority and specificity of COBAS TaqMan HCV assay in an early viral kinetic change during pegylated interferon alpha-2b plus ribavirin treatment. BMC Gastroenterol 2010; 10: 38.
8. Germer JJ, Harmsen WS, Mandrekar JN, Mitchell PS, Yao JD,. Evaluation of the COBAS TaqMan HCV test with automated sample processing using the MagNA pure LC instrument. J Clin Microbiol 2005; 43: 293-298.
9. Lindh M, Alestig E, Arnholm B, et al,. Response prediction and treatment tailoring for chronic hepatitis C virus genotype 1 infection. J Clin Microbiol 2007; 45: 2439-2445.
10. Dahari H, Shudo E, Cotler SJ, Layden TJ, Perelson AS,. Modelling hepatitis C virus kinetics: the relationship between the infected cell loss rate and the final slope of viral decay. Antivir Ther 2009; 14: 459-464.
11. Ge D, Fellay J, Thompson AJ, et al,. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401.
12. Lindh M, Lagging M, Farkkila M, et al,. Interleukin 28B gene variation at rs12979860 determines early viral kinetics during treatment in patients carrying genotypes 2 or 3 of hepatitis C virus. J Infect Dis 2011; 203: 1748-1752.
13. Drusano GL, Preston SL,. A 48-week duration of therapy with pegylated interferon alpha 2b plus ribavirin may be too short to maximize long-term response among patients infected with genotype-1 hepatitis C virus. J Infect Dis 2004; 189: 964-970.
14. Berg T, Weich V, Teuber G, et al,. Individualized treatment strategy according to early viral kinetics in hepatitis C virus type 1-infected patients. Hepatology 2009; 50: 369-377.
15. Sarrazin C, Schwendy S, Moller B, et al,. Improved Responses to Pegylated Interferon Alfa-2b and Ribavirin by Individualizing Treatment for 24-72 Weeks. Gastroenterology 2011; 141: 1656-1664.
16. Adiwijaya BS, Hare B, Caron PR, et al,. Rapid decrease of wild-type hepatitis C virus on telaprevir treatment. Antivir Ther 2009; 14: 591-595.
17. Fried MW, Hadziyannis SJ, Shiffman ML, Messinger D, Zeuzem S,. Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection. J Hepatol 2011; 55: 69-75.